問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Veterans General Hospital

Division of Thoracic Medicine

List

282Cases

2016-07-01 - 2020-12-31

Others

Completed
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF CARBOPLATIN PLUS ETOPOSIDE WITH OR WITHOUT ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER

  • Condition/Disease

    SMALL CELL LUNG CANCER

  • Test Drug

    ATEZOLIZUMAB

Participate Sites
3Sites

Terminated3Sites

邱昭華
Taipei Veterans General Hospital

Division of Hematology & Oncology

楊政達
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2005-07-01 - 2008-07-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2007-11-14 - 2009-12-29

Phase II/III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Terminated11Sites

2024-07-15 - 2026-08-31

Phase I

Active
A Phase 1, Multicenter, Open-Label, Dose Escalation, and Dose Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of DCSZ11 as a Monotherapy and in Combination in Patients with Advanced or Metastatic Solid Tumors

  • Condition/Disease

    Advanced or Metastatic Solid Tumors

  • Test Drug

    injection

Participate Sites
5Sites

Recruiting5Sites

2025-09-01 - 2033-05-31

Phase III

Not yet recruiting
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY TO EVALUATE PF-08046054/SGN-PDLlV VERSUS DOCETAXEL IN ADULT PARTICIPANTS WITH PREVIOUSLY-TREATED PROGRAMMED CELL DEATH LIGAND 1 (PD-Ll) POSITIVE NON-SMALL-CELL LUNG CANCER (NSCLC)

  • Condition/Disease

    Non-small Cell Carcinoma 、Non-Small Cell Lung Cancer Metastatic、 Non-Small Cell Lung Carcinoma

  • Test Drug

    Injectables

Participate Sites
6Sites

Recruiting6Sites

2009-11-01 - 2012-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2005-12-01 - 2008-06-01

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-03-13 - 2024-02-15

Phase I/II

Completed
An open phase 1b/2 trial to evaluate the pharmacokinetics, safety, efficacy and pharmacodynamics of PF-06801591 (PD-1 inhibitor) among participants in advanced malignancies

  • Condition/Disease

    NSCLC

  • Test Drug

    PF-06801591

Participate Sites
4Sites

Recruiting2Sites

Terminated2Sites

洪仁宇
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Thoracic Medicine

2010-08-01 - 2012-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2023-07-03 - 2026-12-31

Phase II/III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3 4 5 29
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB